Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis

doi:10.1021/acs.molpharmaceut.7b01164

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物制剂研究中心

	Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis
	Kang, Xuejia 1,4; Zheng, Zenin 1,4; Liu, Zehua 1,4; Wang, Huiyuan1 ; Zhao, Yuge 1,3; Zhang, Wenyuan 1; Shi, Mingjie 1; He, Yang 1; Cao, Yang 2; Xu, Qin 4
刊名	MOLECULAR PHARMACEUTICS
	2018-04
卷号	15 期号:4 页码:1618-1626
关键词	cell-penetrating peptide doxorubicin andrographolide liposome angiogenesis breast cancer
ISSN号	1543-8384
DOI	10.1021/acs.molpharmaceut.7b01164
文献子类	Article
英文摘要	Effective treatment of metastatic (stage N) breast cancers remains a formidable challenge. To address this issue, a cell-penetrating peptide assisted liposomal system was developed for codelivery of doxorubicin and andrographolide. This nanomedicine-based combination therapy showed the ability to inhibit the in vitro migration and invasion of 4T1 cells through the wound healing and transwell invasion assays. Furthermore, this delivery system exhibited the enhanced accumulation in the tumor tissues and deep intratumoral penetration. The synergistic effect of doxorubicin and andrographolide led to an evident inhibition of tumor growth in an orthotopic breast tumor mouse model and efficient prevention of lung metastasis. The therapeutic mechanism was associated with the anti-angiogenesis effect. In conclusion, this nanomedicine-based combination therapy provides a potential method for overcoming metastatic breast cancers.
资助项目	973 Program, China[2014CB931900] ; NFSC[81402883] ; NFSC[81422048] ; NFSC[81673382] ; NFSC[81521005] ; Strategic Priority Research Program of CAS[XDA12050307] ; Scientific Research and Equipment Development Project[YZ201437] ; SANOFI-SIBS Scholarship Program[00000000] ; Youth Innovation Promotion Association of CAS[00000000] ; Fudan-SIMM Joint Research Fund[FU-SIMM20174009]
WOS关键词	CELL-PENETRATING PEPTIDES ; MULTIDRUG-RESISTANT CANCER ; DELIVERY ; ANGIOGENESIS ; THERAPY
WOS研究方向	Research & Experimental Medicine ; Pharmacology & Pharmacy
语种	英语
出版者	AMER CHEMICAL SOC
WOS记录号	WOS:000429283300024
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/279829]
专题	药物制剂研究中心
通讯作者	Xu, Qin; Huang, Yongzhuo
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; 2.Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510405, Guangdong, Peoples R China 3.Nanchang Univ, Coll Pharm, 461 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China; 4.Guangzhou Univ Chinese Med, Inst Trop Med, Guangzhou 510405, Guangdong, Peoples R China;
推荐引用方式 GB/T 7714	Kang, Xuejia,Zheng, Zenin,Liu, Zehua,et al. Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis[J]. MOLECULAR PHARMACEUTICS,2018,15(4):1618-1626.
APA	Kang, Xuejia.,Zheng, Zenin.,Liu, Zehua.,Wang, Huiyuan.,Zhao, Yuge.,...&Huang, Yongzhuo.(2018).Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis.MOLECULAR PHARMACEUTICS,15(4),1618-1626.
MLA	Kang, Xuejia,et al."Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis".MOLECULAR PHARMACEUTICS 15.4(2018):1618-1626.